IMNN Stock Summary and Trading Ideas (Imunon | NASDAQ:IMNN)

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon trades on the NASDAQ stock market under the symbol IMNN.

As of March 30, 2026, IMNN stock price climbed to $2.88 with 32,230 million shares trading.

IMNN has a beta of -1.89, meaning it tends to be less sensitive to market movements. IMNN has a correlation of 0.04 to the broad based SPY ETF.

IMNN has a market cap of $9.79 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, IMNN traded as high as $41.40 and as low as $2.52.

The top ETF exchange traded funds that IMNN belongs to (by Net Assets): VTI, VXF.

IMNN has underperformed the market in the last year with a return of -77.7%, while the SPY ETF gained +12.7%. In the last 3 month period, IMNN fell short of the market, returning -8.6%, while SPY returned -8.2%. However, in the most recent 2 weeks IMNN has outperformed the stock market by returning -3.7%, while SPY returned -4.3%.

IMNN support price is $2.54 and resistance is $2.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNN shares will trade within this expected range on the day.